Wolfgang Roll,Panayiotis Hadjitheodorou,Emmanouil Alevroudis,Kyriaki Kyrou,Giorgos Adamou,Andreas Fesas,Björn Wängler,Carmen Wängler,Ralf Schirrmacher,Mohammad R Pourkhessalian,Charalambia Kalogirou,Ioannis Tsechelidis,Alexis Vrachimis
{"title":"Head to head comparison of [18F]SiTATE versus [18F]DOPA-PET in patients with neuroendocrine tumors.","authors":"Wolfgang Roll,Panayiotis Hadjitheodorou,Emmanouil Alevroudis,Kyriaki Kyrou,Giorgos Adamou,Andreas Fesas,Björn Wängler,Carmen Wängler,Ralf Schirrmacher,Mohammad R Pourkhessalian,Charalambia Kalogirou,Ioannis Tsechelidis,Alexis Vrachimis","doi":"10.1007/s00259-025-07572-w","DOIUrl":null,"url":null,"abstract":"BACKGROUND\r\nIn neuroendocrine tumors molecular imaging methods play a key role, either targeting the somatostatin receptor or catecholamine pathways. [18F]SiTATE is a somatostatin receptor-targeting peptide that uses silicon fluoride acceptor (SiFA) radiochemistry, overcoming disadvantages of Gallium-68 labelled DOTA compounds. Here we present the first prospective data of [18F]SiTATE compared to [18F]DOPA-PET in NET patients.\r\n\r\nMETHODS\r\n38 patients with suspected neuroendocrine tumors were prospectively included. All patients underwent both [18F]DOPA-PET and [18F]SiTATE-PET. The diagnostic performances were compared on a per-patient and per-lesion basis.\r\n\r\nRESULTS\r\n22 of 38 patients did not show [18F]DOPA- or [18F]SiTATE-PET positive disease. [18F]DOPA-PET was rated as the more accurate imaging modality in three cases and [18F]SiTATE-PET in four cases. [18F]SiTATE-PET showed a significantly higher sensitivity on a per lesion basis compared to [18F]DOPA-PET (n = 143; sensitivity [18F]SiTATE: 86.7%; [18F]DOPA: 73.4%; p = 0.016). Relative quantitative uptake values were not significantly different ([18F]SiTATE median Tumor to Background Ratio max (TBRmax): 8.2; [18F]DOPA TBRmax: 6.5; p = 0.247).\r\n\r\nCONCLUSIONS\r\nIn this first prospective study, [18F]SiTATE-PET provided high tumor to background ratios in the majority of NET patients with complementary results to [18F]DOPA-PET.","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"3 1","pages":""},"PeriodicalIF":7.6000,"publicationDate":"2025-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Nuclear Medicine and Molecular Imaging","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00259-025-07572-w","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}
引用次数: 0
Abstract
BACKGROUND
In neuroendocrine tumors molecular imaging methods play a key role, either targeting the somatostatin receptor or catecholamine pathways. [18F]SiTATE is a somatostatin receptor-targeting peptide that uses silicon fluoride acceptor (SiFA) radiochemistry, overcoming disadvantages of Gallium-68 labelled DOTA compounds. Here we present the first prospective data of [18F]SiTATE compared to [18F]DOPA-PET in NET patients.
METHODS
38 patients with suspected neuroendocrine tumors were prospectively included. All patients underwent both [18F]DOPA-PET and [18F]SiTATE-PET. The diagnostic performances were compared on a per-patient and per-lesion basis.
RESULTS
22 of 38 patients did not show [18F]DOPA- or [18F]SiTATE-PET positive disease. [18F]DOPA-PET was rated as the more accurate imaging modality in three cases and [18F]SiTATE-PET in four cases. [18F]SiTATE-PET showed a significantly higher sensitivity on a per lesion basis compared to [18F]DOPA-PET (n = 143; sensitivity [18F]SiTATE: 86.7%; [18F]DOPA: 73.4%; p = 0.016). Relative quantitative uptake values were not significantly different ([18F]SiTATE median Tumor to Background Ratio max (TBRmax): 8.2; [18F]DOPA TBRmax: 6.5; p = 0.247).
CONCLUSIONS
In this first prospective study, [18F]SiTATE-PET provided high tumor to background ratios in the majority of NET patients with complementary results to [18F]DOPA-PET.
期刊介绍:
The European Journal of Nuclear Medicine and Molecular Imaging serves as a platform for the exchange of clinical and scientific information within nuclear medicine and related professions. It welcomes international submissions from professionals involved in the functional, metabolic, and molecular investigation of diseases. The journal's coverage spans physics, dosimetry, radiation biology, radiochemistry, and pharmacy, providing high-quality peer review by experts in the field. Known for highly cited and downloaded articles, it ensures global visibility for research work and is part of the EJNMMI journal family.